Treace is in a hole. They’ve stopped digging. They’re building a ladder. Hopefully, the board has diagnosed the problem accurately. Here’s an update.
Treace is in a Hole, Can it Get Out?

The bunion specialist reported double-digit procedure growth in the third quarter of 2026, but sales still fell 4% to $48.3 million. (making it up in volume?)
So, management is cutting costs.
Operating expenses fell 10%, which brought net loss down to a still high 23% of sales.
Removing interest costs, taxes, depreciation and amortization costs AND making more adjustments on top of that did drag the loss number over breakeven.
Here are the numbers.
Treace Medical Concepts Financial Snapshot
Dollars in millions. Parentheses indicate losses or cash outflows.
| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Sales | $48.25 | $50.21 |
| Gross profit | $38.35 | $39.71 |
| Operating profit / (loss) | $(11.53) | $(15.68) |
| EBITDA | $(9.34) | $(12.81) |
| Adjusted EBITDA | $0.31 | $(2.59) |
| Cash and cash equivalents at September 30 | $7.76 | $7.69 |
Cash on hand excludes marketable securities. The release provides nine-month cash flows, so standalone quarterly free cash flow cannot be calculated from it. The nine-month comparison appears below. EBITDA and adjusted EBITDA are separate non-GAAP measures.
More Procedures and a Different Sales Mix
Treace attributed the revenue decline primarily to a shift toward lower-priced minimally invasive products and fewer bunion procedure kits sold overall.
Distributor orders added another wrinkle. Excluding sales to stocking distributors, bunion kit volume increased and revenue grew at a mid-single-digit rate.
Lower Expenses Narrow the Losses
The bad news: gross profit declined to $38.4 million from $39.7 million.
The ‘good’ news: sales declined more so gross profit margin improved to 79.5% from 79.1%.
Management cut $5.5 million out of costs so operating expenses came in at $49.9 million. Sales and marketing expenses fell to $29.7 million from $34.4 million. R&D also fell, to $4.5 million from $4.7 million. General and administrative expenses also eased.
In short, Treace is in a hole and management decided to stop digging. Cost cuts brought the company’s operating loss to $11.5 million from $15.7 million in 2025. Net loss was $12.6 million, or $0.19 per share, compared with $16.3 million, or $0.26 per share.
How Will Treace Get Back to Profitability?
New products is one way.
Approximately 45% of Lapiplasty surgeon users now incorporate at least one of Treace’s three newer bunion systems, introduced in the third quarter of 2025. That compares with 40% in the second quarter of 2026, suggesting deeper use of the portfolio among existing customers.
The expanding lineup includes the Nanoplasty and Percuplasty minimally invasive bunion systems, alongside products addressing other foot and ankle procedures. SuperBite compression screws extend the company’s offering for foot fusions, while IntelliGuide provides patient-specific planning and cut guides.
Treace also announced positive five-year results from a prospective, multicenter Lapiplasty study.
Cash Burn Rate Slows
For the first nine months, Treace’s cash burn was $0.7 million, down dramatically from $7.9 million a year earlier. But, then they did have to buy more property and equipment, which brought the cash burn to $8.15 million, still much better than last year’s $19.06 million.
All in all, Treace is spending 53% less cash year-to-date. Cash (or securities that can be turned into cash) hit $39.8 million at the September quarter end. The company has $115 million in additional borrowing capacity, subject to conditions.
New Q4 Forecast
For all of 2026, Treace now expects to report $206 million–$210 million in sales, which represents a 1%–3% decline from 2025.
Losses, as measured by the eponymous adjusted EBITDA stat, will probably come in around $1 million–$2 million.
All of these moves are designed to keep Treace healthy enough to fix it’s larger structural and strategic problems. Hopefully, the board has diagnosed those issues accurately.
Source: Treace Medical Concepts
Author
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
Treace reported a 4% sales decline to $48.3 million in Q3 2026 despite double-digit procedure growth, primarily due to a shift towards lower-priced minimally invasive products and fewer bunion kits sold. Management is implementing cost-cutting measures, reducing operating expenses by 10% to narrow losses. New product adoption is increasing among existing Lapiplasty users, indicating a strategy to expand portfolio use and address market shifts.
- Strategic cost reductions, including a 10% drop in operating expenses, aimed to mitigate financial losses.
- New product systems like Nanoplasty, Percuplasty, SuperBite, and IntelliGuide are expanding the portfolio and driving deeper adoption among existing customers.
PhD Lens: Clinical and outcomes impact
Treace introduced new minimally invasive bunion systems, Nanoplasty and Percuplasty, alongside products for foot fusions (SuperBite compression screws) and patient-specific planning (IntelliGuide). These additions expand the company's clinical offerings. Positive five-year results from a prospective, multicenter Lapiplasty study were also announced, providing further long-term clinical evidence for the procedure's efficacy and safety profile.
- New systems like Nanoplasty and Percuplasty offer minimally invasive bunion solutions, while IntelliGuide provides patient-specific planning.
- Positive five-year clinical outcomes from a prospective, multicenter Lapiplasty study reinforce the procedure's long-term efficacy.

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.